[Source: Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]
Analysis of humoral immune responses in chikungunya virus (CHIKV) infected patients and individuals vaccinated with a candidate CHIKV vaccine
Lisa Henss, Constanze Yue, Christine von Rhein, Roland Tschismarov, Lia Laura Lewis-Ximenez, Albert Dölle, Sally A Baylis, Barbara S Schnierle
The Journal of Infectious Diseases, jiz658, https://doi.org/10.1093/infdis/jiz658
Published: 12 December 2019
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe flu like symptoms. The acute symptoms disappear after one week, but chronic arthralgia can persist for years. Here, humoral immune responses in CHIKV-infected patients and vaccinees were analyzed.
Alphavirus neutralization activity was analyzed with pseudotyped lentiviral vectors and antibody epitope mapping was performed with a peptide array.
Greatest CHIKV neutralization activity was observed 60-92 days after onset of symptoms. The amount of CHIKV-specific antibodies, their binding avidity and cross-reactivity with other alphaviruses increased over time. CHIKV and o’nyong-nyong virus (ONNV) were both neutralized to a similar extent. Linear antibody binding epitopes were mainly found in E2 domain B and the acid-sensitive regions (ASRs). In addition, serum samples from healthy volunteers vaccinated with a measles-vectored chikungunya vaccine candidate, MV-CHIK, were analyzed. Neutralization activity in the samples from the vaccine cohort was 2–6-fold lower than in samples from CHIKV-infected patients. In contrast to infection, vaccination only induced cross-neutralization with ONNV and the E2 ASR1 was the major antibody target.
These data could assist vaccine design and enable the identification of correlates of protection necessary for vaccine efficacy.
alphavirus, chikungunya, antibody, neutralization
This content is only available as a PDF.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: firstname.lastname@example.org.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Keywords: Chikungunya fever; Alphavirus; o’nyong-nyong virus; Vaccines.